Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
HR19042 / Jiangsu Hengrui Pharma
NCT05476900: A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.	Completed	2	69	RoW	HR19042 Capsules	Jiangsu HengRui Medicine Co., Ltd.	Autoimmune Hepatitis	03/25	03/25
NCT05016323: A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.	Recruiting	2	210	RoW	HR19042 Capsules, Placebo	Jiangsu HengRui Medicine Co., Ltd.	IgA Nephropathy	02/24	05/24
NCT06922305: Relative Bioavailability Study of HR19042 in Healthy Subjects	Completed	1	18	RoW	HR19042 Capsule, Tarpeyo®, Budenofalk®	Jiangsu HengRui Medicine Co., Ltd.	Primary IgA Nephropathy; Autoimmune Hepatitis	01/24	01/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
HR19042 / Jiangsu Hengrui Pharma
NCT05476900: A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.	Completed	2	69	RoW	HR19042 Capsules	Jiangsu HengRui Medicine Co., Ltd.	Autoimmune Hepatitis	03/25	03/25
NCT05016323: A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.	Recruiting	2	210	RoW	HR19042 Capsules, Placebo	Jiangsu HengRui Medicine Co., Ltd.	IgA Nephropathy	02/24	05/24
NCT06922305: Relative Bioavailability Study of HR19042 in Healthy Subjects	Completed	1	18	RoW	HR19042 Capsule, Tarpeyo®, Budenofalk®	Jiangsu HengRui Medicine Co., Ltd.	Primary IgA Nephropathy; Autoimmune Hepatitis	01/24	01/24